Novo Nordisk has started building its first brand-new manufacturing facility in Denmark since the millennium, saying it plans to spend around DKK 8.5 billion ($1.2 billion) on the plant.
There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback